Financial Contrast: Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)

iBio (NYSE:IBIO) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

7.9% of iBio shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares iBio and Vincerx Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$500,000.00	99.39	-$24.91 million	($1.39)	-1.59
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00

iBio has higher revenue and earnings than Vincerx Pharma. iBio is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

iBio has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Profitability

This table compares iBio and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-73.15%	-45.51%
Vincerx Pharma	N/A	-248.33%	-132.73%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for iBio and Vincerx Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	0	0	3	0	3.00
Vincerx Pharma	0	0	0	0	0.00

iBio presently has a consensus target price of $4.00, indicating a potential upside of 81.00%. Given iBio’s stronger consensus rating and higher possible upside, equities analysts clearly believe iBio is more favorable than Vincerx Pharma.

Summary

iBio beats Vincerx Pharma on 8 of the 12 factors compared between the two stocks.

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.